BioVaxys Technology Corp. (CSE:BIOV)
Canada · Delayed Price · Currency is CAD | Market Cap | 8.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.97M |
| Shares Out | 42.42M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 485,261 |
| Average Volume | 95,912 |
| Open | 0.2000 |
| Previous Close | 0.1900 |
| Day's Range | 0.1950 - 0.2250 |
| 52-Week Range | 0.1700 - 0.7000 |
| Beta | 0.84 |
| RSI | 43.93 |
| Earnings Date | Mar 13, 2026 |
About BioVaxys Technology
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer... [Read more]
Financial Performance
Financial StatementsNews
Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies
VANCOUVER, BC , July 29, 2024 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage biopharmaceutical company developing a portfoli...